Lyell Immunopharma, Inc. Interest Income (Expense), Nonoperating, Net
Lyell Immunopharma, Inc. (LYEL) reported Interest Income (Expense), Nonoperating, Net of $2.18 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:InterestIncomeExpenseNonoperatingNet · last filed 2026-08-06
- Lyell Immunopharma, Inc. interest income (expense), nonoperating, net for the quarter ending 2026-06-30 was $2.18M, a 33.33% decline year-over-year.
- Lyell Immunopharma, Inc. interest income (expense), nonoperating, net for the quarter ending 2026-03-31 was $2.19M, a 43.19% decline year-over-year.
- Lyell Immunopharma, Inc. interest income (expense), nonoperating, net for the quarter ending 2025-12-31 was $2.68M, a 45.61% decline year-over-year.
- Lyell Immunopharma, Inc. interest income (expense), nonoperating, net for the quarter ending 2025-09-30 was $3.27M, a 45.25% decline year-over-year.
- Lyell Immunopharma, Inc. interest income (expense), nonoperating, net for fiscal 2025 was $13.08M, a 45.65% decline from fiscal 2024.
- Lyell Immunopharma, Inc. interest income (expense), nonoperating, net for fiscal 2024 was $24.07M, a 2.62% increase from fiscal 2023.
- Lyell Immunopharma, Inc. interest income (expense), nonoperating, net for fiscal 2023 was $23.45M, a 232.53% increase from fiscal 2022.
- Lyell Immunopharma, Inc. interest income (expense), nonoperating, net for fiscal 2022 was $7.05M, a 505.41% increase from fiscal 2021.
| Period end | Interest Income (Expense), Nonoperating, Net 3 month | Interest Income (Expense), Nonoperating, Net 6 month | Interest Income (Expense), Nonoperating, Net 9 month | Interest Income (Expense), Nonoperating, Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.18M 10-Q · filed 2026-08-06 | $4.38M 10-Q · filed 2026-08-06 | $7.05M derived: sum of 3 quarters · filed 2026-08-06 | $10.32M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.19M 10-Q · filed 2026-05-06 | $4.87M derived: sum of 2 quarters · filed 2026-05-06 | $8.14M derived: sum of 3 quarters · filed 2026-05-06 | $11.41M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $5.94M derived: sum of 2 quarters · filed 2026-03-12 | $9.22M derived: sum of 3 quarters · filed 2026-08-06 | $13.08M 10-K · filed 2026-03-12 |
| 2025-09-30 | $3.27M 10-Q · filed 2025-11-12 | $6.54M derived: sum of 2 quarters · filed 2026-08-06 | $10.40M 10-Q · filed 2025-11-12 | $15.32M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $3.28M 10-Q · filed 2026-08-06 | $7.14M 10-Q · filed 2026-08-06 | $12.06M derived: sum of 3 quarters · filed 2026-08-06 | $18.02M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $3.86M 10-Q · filed 2026-05-06 | $8.78M derived: sum of 2 quarters · filed 2026-05-06 | $14.75M derived: sum of 3 quarters · filed 2026-05-06 | $21.11M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $4.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $10.88M derived: sum of 2 quarters · filed 2026-03-12 | $17.25M derived: sum of 3 quarters · filed 2026-03-12 | $24.07M 10-K · filed 2026-03-12 |
| 2024-09-30 | $5.96M 10-Q · filed 2025-11-12 | $12.33M derived: sum of 2 quarters · filed 2025-11-12 | $19.15M 10-Q · filed 2025-11-12 | $26.23M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-06-30 | $6.36M 10-Q · filed 2025-08-12 | $13.18M 10-Q · filed 2025-08-12 | $20.27M derived: sum of 3 quarters · filed 2026-03-12 | $26.88M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-03-31 | $6.82M 10-Q · filed 2025-05-13 | $13.90M derived: sum of 2 quarters · filed 2026-03-12 | $20.51M derived: sum of 3 quarters · filed 2026-03-12 | $25.77M derived: sum of 4 quarters · filed 2026-03-12 |
| 2023-12-31 | $7.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $13.69M derived: sum of 2 quarters · filed 2026-03-12 | $18.96M derived: sum of 3 quarters · filed 2026-03-12 | $23.45M 10-K · filed 2026-03-12 |
| 2023-09-30 | $6.61M 10-Q · filed 2024-11-07 | $11.87M derived: sum of 2 quarters · filed 2024-11-07 | $16.37M 10-Q · filed 2024-11-07 | $19.82M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-06-30 | $5.26M 10-Q · filed 2024-08-07 | $9.76M 10-Q · filed 2024-08-07 | $13.21M derived: sum of 3 quarters · filed 2025-03-11 | $15.46M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-03-31 | $4.50M 10-Q · filed 2024-05-06 | $7.95M derived: sum of 2 quarters · filed 2025-03-11 | $10.20M derived: sum of 3 quarters · filed 2025-03-11 | $11.15M derived: sum of 4 quarters · filed 2025-03-11 |
| 2022-12-31 | $3.45M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $5.70M derived: sum of 2 quarters · filed 2025-03-11 | $6.66M derived: sum of 3 quarters · filed 2025-03-11 | $7.05M 10-K · filed 2025-03-11 |
| 2022-09-30 | $2.25M 10-Q · filed 2023-11-07 | $3.20M derived: sum of 2 quarters · filed 2023-11-07 | $3.60M 10-Q · filed 2023-11-07 | $3.92M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $952.00K 10-Q · filed 2023-08-08 | $1.35M 10-Q · filed 2023-08-08 | $1.67M derived: sum of 3 quarters · filed 2024-02-28 | $1.94M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $397.00K 10-Q · filed 2023-05-04 | $720.00K derived: sum of 2 quarters · filed 2024-02-28 | $990.00K derived: sum of 3 quarters · filed 2024-02-28 | $1.21M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $323.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $593.00K derived: sum of 2 quarters · filed 2024-02-28 | $811.00K derived: sum of 3 quarters · filed 2024-02-28 | $1.17M 10-K · filed 2024-02-28 |
| 2021-09-30 | $270.00K 10-Q · filed 2022-11-08 | $488.00K derived: sum of 2 quarters · filed 2022-11-08 | $842.00K 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $218.00K 10-Q · filed 2022-08-04 | $572.00K 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $354.00K 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $5.94M 10-K · filed 2023-02-28 | |||
| 2019-12-31 | $8.12M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |